Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
February 15 2024 - 4:30PM
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the
“Company”), a commercial-stage medical device company that develops
and markets customizable, incision-free therapies for the ablation
of diseased tissue, will announce its fourth quarter and full year
2023 financial results after market close on Thursday, March 7,
2024.
Profound management will host a conference call
at 4:30 p.m. ET to review the financial results and discuss
business developments in the period.
Fourth Quarter and Full Year 2023 Results Conference Call
Details: |
Date: |
Thursday, March 7, 2024 |
Time: |
4:30 p.m. ET |
Live Call Registration: |
https://register.vevent.com/register/BI751e786f640f42da89d816e980b66dd6 |
The call will also be broadcast live and
archived on the Company's website at www.profoundmedical.com under
"Webcasts" in the Investors section.
About Profound Medical
Corp.
Profound is a commercial-stage medical device
company that develops and markets customizable, incision-free
therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a
technology that combines real-time MRI, robotically-driven
transurethral ultrasound and closed-loop temperature feedback
control. TULSA-PRO® is designed to provide customizable and
predictable radiation-free ablation of a surgeon-defined prostate
volume while actively protecting the urethra and rectum to help
preserve the patient’s natural functional abilities.
TULSA-PRO® has the potential to be a flexible technology in
customizable prostate ablation, including intermediate stage
cancer, localized radio-recurrent cancer, retention and hematuria
palliation in locally advanced prostate cancer, and the transition
zone in large volume benign prostatic hyperplasia (“BPH”).
TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared
by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an
innovative therapeutic platform that is CE marked for the treatment
of uterine fibroids and palliative pain treatment of bone
metastases. Sonalleve® has also been approved by the China
National Medical Products Administration for the non-invasive
treatment of uterine fibroids and has FDA approval under a
Humanitarian Device Exemption for the treatment of osteoid osteoma.
The Company is in the early stages of exploring additional
potential treatment markets for Sonalleve® where the
technology has been shown to have clinical application, such as
non-invasive ablation of abdominal cancers and hyperthermia for
cancer therapy.
For further information, please
contact:
Stephen KilmerInvestor
Relationsskilmer@profoundmedical.com T: 647.872.4849
Profound Medical (NASDAQ:PROF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Profound Medical (NASDAQ:PROF)
Historical Stock Chart
From Aug 2023 to Aug 2024